— Know what they know.
Not Investment Advice

KRTX NASDAQ

Karuna Therapeutics, Inc.
1W: +3.3% 1M: +3.3% 3M: +50.5% 1Y: +74.2% 3Y: +179.5%
$329.83
Last traded 2024-03-18 — delisted
NASDAQ · Healthcare · Biotechnology · $12.6B mcap · 36M float · 2.25% daily turnover

Income Trends

Revenue
$654K -93.9% ▼
Gross Profit
-$1M -111.0% ▼
Operating Income
-$495M -70.8% ▼
Net Income
-$434M -56.9% ▼
EPS (Diluted)
$-11.73 -34.2% ▼
EBITDA
-$493M -70.2% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2019FY2020FY2021FY2022FY2023
Revenue$0$0$37M$11M$654K
YoY Growth+0.0%+0.0%+0.0%-71.2%-93.9%
Cost of Revenue$58K$145K$506K$1M$2M
Gross Profit-$58K-$145K$36M$10M-$1M
Gross Margin——98.6%89.5%-160.1%
R&D Expenses$25M$43M$128M$224M$364M
SG&A Expenses$21M$28M$53M$76M$131M
Operating Expenses$45M$72M$181M$300M$495M
Operating Income-$45M-$72M-$144M-$290M-$495M
Operating Margin——-389.2%-2723.3%-75654.0%
Interest Expense$945K$0$0$14M$0
Income Before Tax-$44M-$69M-$144M-$275M-$433M
Tax Expense$887K$43K$6K$1M$670K
Net Income-$45M-$69M-$144M-$276M-$434M
Net Margin——-389.0%-2597.9%-66311.9%
EPS (Diluted)$-3.75$-2.59$-4.94$-8.74$-11.73
EBITDA-$43M-$69M-$143M-$260M-$493M
Shares Outstanding12M26M29M32M37M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms